Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)
- Registration Number
- NCT00932867
- Lead Sponsor
- Bayer
- Brief Summary
Surveillance of efficacy and safety of drug PRITOR in patieNts with arterial hypertension, who do not tolerate ACE inhibitoR treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3114
Inclusion Criteria
- Patients over 18 years of age
- Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)
- Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation)
Inclusion criteria for the control arm (treated by ACEi):
- Patients over 18 years of age
- Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)
- Patients, who tolerate ACEi treatment
Read More
Exclusion Criteria
- Cholestasis, severe hepatic insufficiency
- Allergy to telmisartan
- Gravidity or lactation
Exclusion criteria for the arm of patient treated by ACEi:
- Cholestasis, severe hepatic insufficiency
- Allergy to ACEi
- Gravidity or lactation
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Kinzal/Pritor (Telmisartan, BAY68-9291) -
- Primary Outcome Measures
Name Time Method To evaluate efficacy and safety of telmisartan in patients with arterial hypertension, who do not tolerate ACEI treatment 1 year
- Secondary Outcome Measures
Name Time Method